IGM Biosciences is a biotechnology company that develops medicine for people with infectious infections, autoimmune diseases, and cancer.
IGM Biosciences has raised $107.3M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2023.
IGM Biosciences's investors include Vivo Capital, Janus Henderson Investors, Redmile Group, Topsoe, Baker Brothers Advisors LLC.
IGM Biosciences is headquartered in Mountain View, United States.
IGM Biosciences is a biotechnology company that develops medicine for people with infectious infections, autoimmune diseases, and cancer.
IGM Biosciences is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"IGM Biosciences — Funding & Investors." VCBacked, June 22, 2023, https://www.vcbacked.co/company/igm-biosciences. Accessed September 28, 2026.
VCBacked. (2023). IGM Biosciences — Funding & Investors. Retrieved September 28, 2026, from https://www.vcbacked.co/company/igm-biosciences
{{cite web |title=IGM Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/igm-biosciences |website=VCBacked |access-date=September 28, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated